InvivoSciences, Inc. (IVS) news
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. The
BIOtechNOW featured IVS’s participating BIO Innovation Zone
Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies.
The SBIR/STTR program provides U.S. federal fundi
BIO Investor Forum Company Snapshot: InvivoSciences
What is your company’s lead product or technology?
InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D tissue models recapitulate the physiological properties of huma
https://www.termis.org/wc2018/
On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session.
99-O-5: Personalized micro-3D human heart
tissues for orphan drug development
Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli,
Michael Greenberg,Jennifer Strande
InvivoSciences, Inc. Madison Wisconsin, USA, Washington University, S